CMS makes it official, codifying Medicare drug price negotiations established under IRA

Patients will soon notice a shift in how their Medicare prescriptions are priced, a surprise given the program’s relatively new status. While the Inflation Reduction Act introduced drug price negotiations, the latest CMS rule makes a fourth round official, raising expectations that drug costs could drop but also prompting worries about access delays for cancer treatments. For many seniors, even modest price shifts can affect medication adherence and out‑of‑pocket budgeting.

The American Hospital Association’s release confirmed the rule’s adoption, while Bloomberg Law News detailed the administration’s final steps toward implementation, signaling a concrete move from policy to practice. The rule also clarifies negotiation mechanics, including eligibility criteria for drug inclusion, a detail highlighted by the administration’s briefing. Fierce Pharma noted the rule’s official status, and RealClearHealth warned that the new requirements could cost cancer patients additional time.

TradingView reported Halozyme Therapeutics expects zero to minimal royalty impact through 2035, illustrating that some firms anticipate limited financial effect. Stakeholders will watch how CMS operationalizes the negotiations and whether supplemental guidance addresses the timing concerns raised by patient groups. How the rule will translate into actual pricing changes and patient experience remains an open question.